Baseline observations from the POSSIBLE EU® study: Characteristics of postmenopausal women receiving bone loss medications

被引：12

作者：

Freemantle N.

Cooper C. ^{[1
,2
]}

Roux C. ^{[3
]}

Díez-Pérez A. ^{[4
]}

Guillemin F. ^{[5
]}

Jonsson B. ^{[6
]}

Ortolani S. ^{[7
]}

Pfeilschifter J. ^{[8
]}

Horne R. ^{[9
]}

Kakad S. ^{[10
]}

Shepherd S. ^{[11
]}

Möller G. ^{[13
]}

Marciniak A. ^{[12
]}

Martinez L. ^{[14
]}

机构：

[1] MRC Epidemiology Resource Centre, University of Southampton, Southampton

[2] Institute of Musculoskeletal Sciences, University of Oxford, Oxford

[3] Department of Rheumatology, Paris Descartes University, Cochin Hospital, Paris

[4] Dept. de Medicina, Hospital Del Mar IMIM-UAB-RETICEF, Barcelona

[5] Nancy-University

[6] Stockholm School of Economics, Stockholm

[7] Istituto Auxologico Italiano, Milan

[8] Klinik für Innere Medizin III, Alfried Krupp Krankenhaus, Essen

[9] Centre for Behavioural Medicine, School of Pharmacy, University of London, London

[10] Clinical Research, Amgen Ltd, Uxbridge

[11] Biostatistics, Amgen Ltd, Uxbridge

[12] Health Economics, Amgen Ltd, Uxbridge

[13] International Development, Amgen (Europe) GmbH, Zug

[14] Société Française de Médecine Générale, Issy les Moulineaux

来源：

Archives of Osteoporosis | 2010年 / 5卷 / 1-2期

关键词：

Cohort studies; Osteoporosis; Postmenopausal osteoporosis; Prospective studies;

D O I：

10.1007/s11657-010-0035-7

中图分类号：

学科分类号：

摘要：

Prospective Observational Scientific Study Investigating Bone Loss Experience in Europe (POSSIBLE EU®) is an ongoing longitudinal cohort study that utilises physician- and patient-reported measures to describe the characteristics and management of postmenopausal women on bone loss therapies. We report the study design and baseline characteristics of 3,402 women recruited from general practice across five European countries. Purpose: The POSSIBLE EU® is a study describing the characteristics and management of postmenopausal women receiving bone loss medications. Methods: Between 2005 and 2008, general practitioners enrolled postmenopausal women initiating, switching or continuing treatment with bone loss treatment in France, Germany, Italy, Spain and the UK. Patients and physicians completed questionnaires at study entry and at 3-month intervals, for 1 year. Results: Of 3,402 women enrolled (mean age 68.2 years [SD] 9.83), 96% were diagnosed with low bone mass; 55% of these using dual energy X-ray absorptiometry. Most women (92%) had comorbidities. Mean minimum T score (hip or spine) at diagnosis was -2.7 (SD 0.89; median -2.7 [interquartile range, -3.2, -2.2]) indicating low bone mineral density. Almost 40% of the women had prior fractures in adulthood, mostly non-vertebral, non-hip in nature, 30% of whom had at least two fractures and more than half experienced moderate/severe pain or fatigue. Bisphosphonates were the most common type of bone loss treatment prescribed in the 12 months preceding the study. Conclusions: POSSIBLE EU® characterises postmenopausal women with low bone mass, exhibiting a high rate of prevalent fracture, substantial bone fragility and overall comorbidity burden. Clinical strategies for managing osteoporosis in this population varied across the five participating European countries, reflecting their different guidelines, regulations and standards of care. © 2010 The Author(s).

引用

页码：61 / 72

页数：11

共 19 条

[1]

Siris E.S., Bilezikian J.P., Rubin M.R., Black D.M., Bockman R.S., Bone H.G., Hochberg M.C., McClung M.R., Schnitzer T.J., Pins and plaster aren't enough: A call for the evaluation and treatment of patients with osteoporotic fractures, Journal of Clinical Endocrinology and Metabolism, 88, 8, pp. 3482-3486, (2003)

[2]

Roux C., Briot K., Horlait S., Varbanov A., Watts N.B., Boonen S., Assessment of non-vertebral fracture risk in postmenopausal women, Annals of the Rheumatic Diseases, 66, 7, pp. 931-935, (2007)

[3]

Osteoporosis in the European Union in 2008: Ten Years of Progress and Ongoing Challenges, (2008)

[4]

Seeman E., Compston J., Adachi J., Brandi M.L., Cooper C., Dawson-Hughes B., Jonsson B., Pols H., Cramer J.A., Non-compliance: The Achilles' heel of anti-fracture efficacy, Osteoporosis International, 18, 6, pp. 711-719, (2007)

[5]

Kanis J.A., Burlet N., Cooper C., Et al., European guidance for the diagnosis and management of osteoporosis in postmenopausal women, Osteoporos Int, 19, pp. 399-428, (2008)

[6]

Barrett-Connor E., Ensrud K., Tosteson A., Et al., Design of the POSSIBLE US™ study: Postmenopausal women's compliance and persistence with osteoporosis medications, Osteoporosis Int, 20, pp. 463-472, (2009)

[7]

Brooks R., De Charro F., EuroQol: The current state of play, Health Policy, 37, 1, pp. 53-72, (1996)

[8]

EuroQol-a new facility for the measurement of health-related quality of life, Health Policy, 16, pp. 199-208, (1990)

[9]

EuroQol Group EQ-5D, EuroQol Group Rotterdam

[10]

Silverman S., The Osteoporosis Assessment Questionnaire (OPAQ): A reliable and valid disease-targeted measure of health-related quality of life (HRQOL) in osteoporosis, Qual Life Res, 9, pp. 767-774, (2000)

← 1 2 →